maybe we could start — we’re already towards the end of 2022, and I think people’s attention are really shifting to next year just with so many moving pieces, both in revenues and down the P&L with currency and inflation and COVID testing assumptions and so on, so I was hoping so...
中国上海和韩国首尔2022年7月8日全球领先的生物偶联药CRDMO服务公司药明合联(WuXi XDC)与专注抗体偶联药物开发的韩国生物技术公司AbTis今日宣布,双方已针对AbTis公司的抗体偶联药物(ADC)产品管线签署合作备忘录。根据合作备忘录,AbTis公司...
I do think that in 2023 there will be renewed focus on how money flows through the travel system. A review of the ATOL scheme is already under way, in addition to the Chancellor’s plans, and I know that many travel companies are looking afresh at their payment terms and conditions. And...